Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 20/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 15/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13229550 | 1.00 | CYP19A1 (0.37) | CYP19A1CYP11B2CYP11B1 | |
| SCHEMBL13229253 | 0.93 | CYP19A1 (0.42) | CYP19A1CYP11B2CYP11B1 | |
| SCHEMBL13229104 | 0.93 | CYP19A1 (0.42) | CYP19A1CYP11B2CYP11B1 | |
| SCHEMBL13229552 | 0.85 | TYRO3 (0.37) | CYP19A1CYP11B2CYP11B1 | |
| SCHEMBL13229100 | 0.81 | CYP11B1 (0.32) | CYP11B2CYP11B1 | |
| SCHEMBL13229272 | 0.81 | CYP11B1 (0.32) | CYP11B2CYP11B1 | |
| SCHEMBL13229518 | 0.80 | CYP19A1 (0.39) | CYP19A1CYP11B2CYP11B1 | |
| SCHEMBL4226665 | 0.78 | CYP19A1 (0.44) | CYP19A1CYP11B2CYP11B1 | |
| SCHEMBL4234962 | 0.78 | CYP19A1 (0.48) | CYP19A1CYP11B2CYP11B1 | |
| SCHEMBL4226486 | 0.78 | CYP11B2 (0.44) | CYP19A1CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501747-B2 | Functionally selective alpha2C adrenoreceptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501747-B2 | Functionally selective alpha2C adrenoreceptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20100197562-A1 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION AND PHARMACOPEIA, LLC (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197562-A1 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION AND PHARMACOPEIA, LLC (US) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197562-A1 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | ADRA2C, ADRB2, ADRB3 | CYP19A1 1087/4885CYP11B2 114/4885CYP11B1 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.